Q3 2023 Amneal Pharmaceuticals Inc Earnings Call
Okay.
Okay.
Okay.
Okay.
[music].
Okay.
[music].
Okay.
Speaker 1: Good morning and welcome to the Amneal third quarter 2073 earnings call. I will now turn the call over to Amneal's head of investor relations, Tony DeMio.
Good morning, and welcome to the unknown that work has been to some degree any code.
I will now turn the call over to unveil head of Investor Relations and EMEA.
Speaker 2: Good morning. And thank you for joining AMNEL Pharmaceuticals' third quarter 2023 Ernie's call. Today, we should oppress release reporting our Q3 results. We announce certain unordered preliminary results for Q3 on October 23rd. Our earnings press release and presentation are available at AMNEL.com.
Good morning, and thank you for joining annual Pharmaceuticals third quarter 2023 earnings call.
Today, we issued a press release reporting our Q3 results, we announced certain on.
Preliminary results for Q3 on October 23rd.
Our earnings press release and presentation are available at <unk> Dot com.
Speaker 2: Certain statements made on this call regarding matters that are not historical facts. Including, but not limited to management outlook or predictions are forward looking statements. That are based solely on information that is now available to us.
Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions are forward looking statements that are based solely on information that is now available to us.
Speaker 2: Please see the section entitled cautionary statements on forward looking statements in the earnings presentation and our SEC filings for discussion of factors that may impact our future performance. to the Ethiopians doing nothing is a formula and it's time to face our own questions all employees are WOMBLING we all did
Please see the section entitled cautionary statements on forward looking statements in the earnings presentation, and our SEC filings for a discussion of factors that may impact our future performance.
We also discuss non-GAAP measures.
Speaker 2: Information on our use of these measures and reconciliation to US GAAP are in the earnings presentation.
Information on our use of these measures and reconciliations to U S. GAAP in the earnings presentation.
Speaker 2: On the call today are Sharag and Shinsu Patel, co-founders and co-CEOs. Tasos Konideris, CFO . Our commercial leaders, Andy Boyer for Jadarix, Joe Renda for Specialty, Harsher Singh for Biosciences, and Jason Daley, Chief Legal Officer. I will now hand the call over to Sharag.
On the call today are <unk> <unk> co founders and co Ceos fastest Tony Darren CFO, our commercial leaders, Andy Boyer for generics, Joe random for specialty harsher seeing for Biosciences, and Jason Daly, Chief Legal Officer, I will now hand, the call over to Sharon.
Speaker 3: Thank you. Thank you, Tony. And good morning, everyone. We delivered another very strong quarter with 620 million of revenue, which is up 14%, adjusted a bit of 154 million, up 22%, and adjusted EPS of $0.19, up 36%.
Thank you. Thank you Tony and good morning, everyone.
We delivered another very strong quarter with $620 million of revenue, which is up 14% adjusted EBITDA of 154 million up 22% and adjusted EPS of <unk> 19 cents.
Up 36% we.
Speaker 3: We saw growth in all three of our business segments and reduced net leverage to force 0.6 times.
We saw growth in all three of our business segments and reduce net leverage to force more than six times.
Speaker 3: Given the strength of our year-to-date performance, we are pleased again to raise our full year 2020 guidance.
Given the strength of our year to date performance.
We're pleased again.
Today's over full year 2020 guidance.
Speaker 3: We are excited about our continued momentum, which underscores the strength of our strategy and solid execution.
We are excited about our continued momentum, which underscores the strength of our strategy and solid execution as.
Speaker 3: As we have discussed throughout the year, we believe Emm Neil is at an inflection point, poised to drive significant top and bottom line in 2024 and beyond.
As we have discussed throughout the year, we believe that Neil is that an inflection point.
This to drive significant top and bottom line in 2024 and beyond.
Speaker 3: I'll start with a quick overview of our company and then walk through what we saw in each of our businesses during the third quarter.
I'll start with a quick overview of our company and then work through what we saw in each of our businesses during third quarter.
Speaker 3: At a high level, M-Neil is a world-class, global, diversified, pharmaceutical company fulfilling our mission to provide access to high quality and affordable essential medicines. In our...
At a high level and Neil is a world class global diversified pharmaceutical company.
Wholesaling, our mission to provide access to high quality and affordable essential medicines.
In our affordable medicines business.
Speaker 3: Our generic segment, we have retail, injectables, biosimilars and internationals.
Oh, the generics segment.
We have retail Injectables Biosimilars and international.
Our strategy continues to focus on expanding our portfolio with impactful complex and high level.
Speaker 3: Our strategy continues to focus on expanding your portfolio with impactful, complex, and high-level, high-value products.
High value products.
Speaker 3: For the first nine months of 2023, generics revenues were up 7% compared to last year, reflecting a meaningful acceleration from the steady 3% CAGR we delivered from 2019 to 2022.
For the first nine months of 2023 generics revenues were up 7% compared to last year.
Reflecting a meaningful acceleration from this steady 3% CAGR, we delivered from 2019 to 2022.
We expect high level digit or high single digit top line growth in generics to continue driven by our diverse portfolio and cadence of over 30, new product launches every year.
Speaker 3: We expect high level digit, high single digit top line growth in generics to continue. They won by our diverse portfolio and cadence of over 30 new product launches every year.
Speaker 3: In Injectable, our goal is to be top five in the United States institutional market.
In injectable or the goal is to be.
Top five in the United States.
Institutional market.
Speaker 3: There are two key factors that we believe differentiates M-NEAL and will drive our success. The first is expanding capacity and capabilities. And the second is an expanding portfolio. In 2023, we have executed on both. We successfully brought online two new sites, which doubled our manufacturing capacity.
There are two key factors that we believe differentiates our meal and will drive our success.
The first is expanding capacity and capabilities and the second is an expanding portfolio in 2023 were executed on both we successfully brought online two new sites, which doubled our manufacturing capacity.
Speaker 3: Currently, we have 35 commercial injectables with over 25 new launches planned by 2025 as we continue increasing production and expanding your portfolio. In a market like by shortages, we are well positioned for higher injectables revenues in 2024 and over $300 million by 2025.
Currently we have 35 commercial injectables with over 25, new launches planned by 2025, as we continue increasing production and expanding our portfolio in a market like by shortages, we are well positioned for higher injectables revenues in 2024.
And over $300 million by 2025.
In Biosimilars.
Speaker 3: Our three commercial products continue to see strong uptake. Our largest product, Alimsis.
Our three commercial products continue to see strong uptake.
Our largest product of lenses.
Speaker 3: was at 6% market share as of September , which is remarkable in the first three quarters post launch.
Is that 6% market share as of September which is remarkable in the first three quarters post launch we.
Speaker 3: We expect 60 million in biosimilar cells this year, more than double that next year, and over 200 million in 2025.
We expect 60 million in Biosimilar sales this year more than double that next year and over $200 million in 2025.
Speaker 3: In addition, we expanded our partnership with Map Science, who we worked with on Alimpsis to add two formulations of the Nossumap and on Kojiba are similar.
In addition, we expanded our partnership with life Science, who we work with on lenses to add two formulations of the notes to map.
And oncology Biosimilar to our pipeline.
Speaker 3: This is part of the next basket of Basimilus for Amnia. By 2024, we look to add two to three more Basimilus to the pipeline. We see Basimilus as the next wave of affordable medicines and are committed to being a leader in this space.
This is part of the next basket of Biosimilars for revenue by 2024, we'll look to add to see more biosimilars to the pipeline.
We see Biosimilars as the next wave of affordable medicines and are committed to being a leader in this space.
Speaker 3: Internationally, we're leveraging our USFT approved portfolio to expand our reach and drive profitable growth. In India, we have our local infrastructure and our expanding of a local portfolio. In other geographies.
Internationally, we are leveraging our U S FDA approved portfolio to expand our reach and drive profitable growth.
In India, we have.
Our local infrastructure and are expanding our local portfolio in other geographies.
Speaker 3: We are working with partners to commercialize our products. For example, we now have two products approved in China. We expect international expansion will add 5200 million revenues by 2027 and scale further over time.
We are working with partners to commercialize our products. For example, we now have two products approved in China, We expect international expansion, which will add $50 million to $100 million revenues by 2027 and scale further over time.
Speaker 3: In our affordable innovations business specialty segment, we are focused on neurology and endocrinology therapeutic areas.
In our affordable innovations business.
Specialty segment, we are focused on neurology and endocrinology therapeutic areas.
Speaker 3: Our commercial teams continue to drive growth in our key branded product.
Our commercial teams continue to drive growth in our key branded products dietary for Parkinson's and units for hypothyroidism as.
Speaker 3: Battery for Parkinson's and unithroid for hypothyroidism. As you know, we received a CRL for IPX 203 seeking additional data in July . I'm pleased to report that we had a successful type in meeting with FTL last month, and we are working diligently towards the 2020 for approval and launch, which in through will discuss shortly.
As you know we received a CRA elsewhere IPX, two or three seeking additional data in July.
Pleased to report that we had a successful type a meeting with FDA last month, and we are working diligently towards that 2020 for approval and launch with Chengdu will discuss shortly.
Speaker 3: We expect specialty revenues to be over $500 million by 2027.
We expect specialty revenues to be over $500 million by.
By 2027.
Speaker 3: Finally, in our FK segment, we continue to see robust growth across all three channels, distribution government, VADOD, unit dollars.
Finally, you know whatever care segment, we continue to see robust growth across all three channels distribution government.
Unit dose.
Speaker 3: We expect the evcare revenue of 500 million in 2023, and over $600 million by 2025. All now.
We expect care.
Revenue of $500 million in 2023 and over $600 million by 2025.
I will now pass it to children.
Speaker 3: Good morning, everyone. Thank you, Cheerdargs, and thank you to the global M. Nile family who work hard every day to help make healthy possible for so many. We are laser focused on executing our strategy to be an innovative and diversified global pharmaceutical company, capable of driving sustainable growth in the key areas of mind.
Good morning, everyone. Thank you two dogs and thank you to the global <unk> family.
Work hard every day to help make healthy, possibly well for so many we are laser focused on executing our strategy to be an innovative and diversified global pharmaceutical company.
People are driving sustainable growth in the key areas of medicine.
Speaker 3: The successes of 2023 are clear proof points that we are on the right track. I will touch on how operational excellence strong supply chain and highly productive are ending engine, proper lower strategy.
Successes of 2023 are clear proof points that we are on the right track I will touch on how operational excellence strong supply chain and highly productive R&D engine properly. Our strategy first we remain focused on driving operational excellence and efficiency as Anil has one.
Speaker 3: First, we remain focused on driving operational excellence and efficiency as Amnil has one of the best service levels in the industry. As part of our efforts to drive continuous cost efficiency globally, we are transferring production for about 30 products for cost improvement and also working on many operational excellence programs for long term savings.
The best service levels in the industry as part of our efforts to drive continuous cost efficiencies globally. We are transferring production for about 30 products for cost improvement and also working on menu operational excellence programs for long term savings. In addition, we have.
Speaker 3: In addition, we have strengthened our supply chain by expanding our infrastructure, particularly in injectables.
Strength in our supply chain by expanding our infrastructure, particularly in Injectables, we have doubled our injectables capacity with full facilities and 19 production lines widely injectables market continue to face supply shortages.
Speaker 3: We have doubled our injectables capacity with full facilities and 19 production lines. While the injectables market continue to face supply shortage.
Speaker 3: Importantly, about 30 of our commercial A&DA and pipeline injectable products are on the US FDA shortage list. Amnil is very well positioned to help address drug shortages in the US.
Importantly, about 30 of our commercial NDA and pipeline injectable products are on the U S. FDA shortage list.
He is very well positioned to help address drug shortages in the U S. At.
Speaker 3: At the same time, we remain committed to maintaining our stellar quality track record. Since 2005, the US FDA has conducted nearly 100 successful inspections with no observations or only minor 480 degrees. Overall, our high-quality global operations are at scale to support sustainable long-term growth.
At the same time, we remain committed to maintaining a was tailored quality track record since 2005. The U S. FDA has conducted nearly 100 successful inspections with no observations are only minor 480 threes overall, our high quality.
Global operations are at scale to support sustainable long term growth.
Speaker 3: Second, innovation is the lifeblood of any growing pharmaceuticals company. And that's certainly the case for Amdian. In generics, we are on track for over 40 new launches in 2023, with 33 year to date.
Second innovation is the lifeblood of any growing pharmaceutical company and that's certainly the case for everyone. In generics. We are on track for over 40, new launches in 2023.
33 year to date.
Speaker 3: This is well above our normal cadence of 30 per year. Also, it's more than just the number of new launches. It is the complex area of these products, less competitors, and the increased value of our diversity by portfolio.
This is well above our normal cadence of 30 per year.
So it's more than just the number of new launches. It is the complexity of these products less competitors and the increased value of our diversified portfolio.
Speaker 3: Our pipeline is deep with 166 products pending approval or in development.
Our pipeline is deep with 166 broad expanding approval or in development.
Speaker 3: Accordingly, we expect over 30 new launches next year.
Accordingly, we expect over 30, new launches next year.
Speaker 3: and for years after that. In addition, while we have shifted towards complex innovations, we have also improved the efficiency of our R&D operations. We are doing more R&D with less spend, which results in a better ROI on projects. Let me share some more details.
And for the years after that in addition, while we have shifted towards complex innovations. We have also improved the efficiency of our R&D operations. We are doing more R&D with less spend which resulted in a better ROI on projects, let me share some more details on R&D.
Speaker 3: Overall, we have 88 ANDAs spending with FDA, of which 64% are non-oral solid products.
Overall, we have 88, andas pending with FDA of which 64% are non oral solid products behind that we have 78 pipeline products of which 90% are non oral solids, we have shifted our focus to high value complex categories with.
Speaker 3: Behind that we have 78 pipeline products of which 90% are non-oral solid.
Speaker 3: We have shifted our focus to high value complex categories with approximately 45% of pending A and A than over 60% of our pipeline expected to be first to market, first to file or 552 products.
Approximately 45% of pending andas and over 60% of our pipeline.
Expect it to be first to market first to file our 500 <unk> two products in.
Speaker 3: In injectables we have launched 10 new products here to date, including two high-value products in Q3 with potassium phosphate and calcium gluconec bags.
In Injectables, we have launched 10, new products year to date, including two high value products in Q3 with production phosphate and calcium gluconate bags.
Speaker 3: Also, we recently received approval for M-P-MITAL Pregnissolone Acetate, which is in shortage. Further, we are advancing a number of complex injectables in our pipeline. In Q3, we find our first...
Also we recently received approval for <unk> retail prednisolone acetate, which is in shortage. Further we are advancing a number of complex injectables pipeline in Q3, we filed our first two.
Speaker 3: 255B2 ready-to-use bags as planned. We expect to file several long-acting injectables in the near term as well. As a result, we expect a strong cadence of impactful new injectables to continue in 2024, including the launch of already approved PAMBRIDI RTU.
Firefly do ready to use bags as planned we expect to file several long acting injectables in the near term as well as a result.
The strong cadence of impactful new injectables to continue into enduring before including the launch of already approved family.
Hugh.
Speaker 3: After injectables, we see inhalation as amnils next key growth area in complex scenarios.
After injectables, we see inflation as <unk> next key growth area.
In complex generics.
Speaker 3: Our pending A&DF for generic version of Narcan is under priority review and we look to launch in the coming months upon approval. This is important over the counter product improves access to a critical overdose treatment.
Our pending Anda for generic version of Narcan is under priority review and we look to launch in the coming months upon approval.
These important over the counter product improves access to critical overdose chip.
Speaker 3: In addition, we have two key meteredo's inhaler A and D.A.s, pending for generic version of QR and ProF. In biosimilers or first three oncology product fasting, excellent update, and we have added two additional molecules to the pipeline. We are also evaluating opportunities to be vertically integrated over time. Please see our catalyst slide for the list of recent and up-capping launches.
In addition, we have two key metered dose inhaler andas pending for generic version of cure and brought it in.
In Biosimilars or firstly oncology products are seeing excellent uptake and we have added two additional molecules to the pipeline. We are also evaluating opportunities to be vertically integrated over time. Please see our catalyst slide for the list of recent and upcoming launches.
Speaker 3: Turning to specialty R&D, we continue to work to advance our 5.5b2 pipeline. On IPX203, as Chirag highlighted, we had a successful type A meeting with FDA last month to align on the path to approval. As agreed with FDA, we are in the process of completing a small routine QT study in healthy patients.
Turning to specialty R&D, we continue to work to advance our <unk> pipeline or IPX, two or three as Doug highlighted we had a successful type a meeting with FDA last month to align on the path to approval as agreed with FDA. We are in the process of.
Completing a small routine qt study in healthy patients.
Speaker 3: We will complete the study in the coming months and we will resummit our NDA in early 2024. We are working diligently towards an IPX 203 launch in the second half of 2024, bending FDA approval. We continue to see IPX 203 as a critical innovation that meaningfully advances the standard of care for Parkinson's patients.
We'll complete the study in the coming months and we will resubmit our NDA in early 2024.
We are working diligently towards an IPX towards re launch in the second half of 'twenty 'twenty four pending FDA approval, we continue to see IPX, two or three as a critical innovation that meaningfully advances the standard of care for Parkinson's patients in summary.
Speaker 4: In summary, we are driving operational excellence and executing our innovation strategy, which together are fueling our ability to drive sustainable growth. I will now hand it over to Tasos. Thank you, Chintu. Let me first start with the four pillars of value creation from Ennio. That is diversification, strong financial
Driving operational excellence and executing our innovation strategy, which together are fueling our ability to drive sustainable growth I will now hand, it over to Carlos. Thank you Chengdu, Let me first start with the four pillars of value creation for menu that is diversification.
<unk>.
Strong financial performance.
Speaker 4: cash generation, and fourth, overall debt reduction.
Cash generation and fourth overall debt reduction.
Speaker 4: First, starting with increased diversification. Sirag and Chintu touched on this throughout their overview of MNEL's strategy and business highlights.
First starting with increased diversification <unk> touched on this throughout the rubber view of M&A strategy and business highlights.
Speaker 4: Since 2019, the portfolio is remarkably more diversified with new lines of business.
2019, the portfolio's remarkably more diversified with new lines of business.
Speaker 4: In 2019, oral solid generics represented 53% of total revenue.
In 2019 oral solid generics represented 53% of total revenue.
Speaker 4: Now, in 2023, with new complex generic launches, growth in injectables and specialty, and the addition of biosimilars and upcar, the portion of oral solid generic revenue is less than half of that, at only 26% of the total company revenue.
Now into 2020, three with new complex generic launches.
Both in Injectables and specialty and the addition of Biosimilars and after that portion of oral solid generic revenue is.
It's less than half of that at only 26% of the total company revenues.
The higher level of diversification was intentional and driven by our desire to deliver consistent financial performance. Despite the typical ups and downs of any business.
Speaker 4: The higher level of diversification was intentional and driven by our desire to deliver consistent financial performance, despite the typical ups and downs of any business.
As a result, our diversified portfolio is driving sustainable higher levels of growth and profitability as well as increased future visibility.
Speaker 4: As a result, a diversified portfolio is driving sustainable higher levels of growth and profitability, as well as increased future visibility.
Speaker 4: Let me now move to our second pillar of strong financial performance.
Let me now move to our second pillar of strong financial performance.
Speaker 4: As an example, since 2019, our annual revenues have increased by over 800 million dollars, or 50 percent, while adjusted EBITDA is up about 200 million dollars, or 60 percent.
As an example, since 2019, our annual revenues have increased by over $800 million.
Our 50%.
While adjusted EBITDA is up about $200 million or.
Over 60%.
Speaker 4: Consequently, our third quarter strong financial performance is not an isolated event and reflects strong execution across our strategic choices for a number of quarters and years.
Consequently, our third quarter strong financial performance is not an isolated event and reflects strong execution across our strategic choices for a number of quarters and years.
Speaker 4: Let me now go into a bit more detail of our third quarter results.
Let me now go into a bit more detail of our third quarter results.
Speaker 4: Total net revenue was $620 million, growing 14%.
Total net revenue was $620 million growing 14%.
Speaker 4: adjusted EBDA over 154 million, growing 22%.
Adjusted EBITDA of 154 million growing 22%.
Speaker 4: adjusted EPS of 19 cents, growing 36 percent.
Adjusted EPS of 19.
Growing 36%.
Speaker 4: All three business segments grew revenue substantially this quarter.
All three business segments grew revenue substantially this quarter.
Speaker 4: Q3 generics net revenue was $391 million, growing 12%, driven by our new biosimilars and new complex generics as new launches in 2023 and 2022 added $40 million in Q3 revenue growth.
Q3, generics net revenue was $391 million growing 12% driven by our new Biosimilars, a new complex generics as new launches in 2023, and 2022 added $14 million in Q3 revenue growth.
Speaker 4: The acceleration in generics growth in 2023 reflects the continued shift towards a diverse, complex portfolio and the addition of key new products that are additive to growth.
The acceleration in generics growth in 2023 reflects the continued shift towards a diverse.
Complex portfolio and the addition of key new products that are.
Keep the growth.
Next in specialty net revenue was 97 million growing 9% driven by unit throw it in Rytary.
Speaker 4: Next in specialty net revenue was 97 million, growing 9% driven by unit, throw it in right.
Q3, after net revenue of 132 million grew 25%, which reflects strong execution and new product introductions by the team.
Speaker 4: Q3 after net revenue of 132 million, grew 25% which reflects strong execution and new product introductions by the team.
Speaker 4: Q3 adjusted EBITDA over $154 million reflects strong revenues, durable gross margins, and tight expense management.
Q3, adjusted EBITDA of 154 million reflects strong revenues during both gross margins and tight expense management.
Looking at our Q3 year to date results.
Speaker 4: Total company revenue growth is 11% with generics up 7%.
Total company revenue growth is 11% with generics up 7%.
Speaker 4: Specifically growing at 5% and now you're growing at 28%.
Especially I think growing at 5% and novocure growing at 28%.
Speaker 4: Combined with stable gross margins and operating expense leverage, year-to-date adjusted EBITDA grew 16 percent and adjusted EPS grew 11 percent.
Combined with stable gross margins and operating expense leverage year to date, adjusted EBITDA grew 16% and adjusted EPS grew 11%.
Speaker 4: Let me now move to our 2023 full year guidance.
Let me now move to our 2023 full year guidance.
Speaker 4: were given the continued stromper formats across the business for raising a full year, 2023 expectations again this court.
We are given the continued strong performance across the business, we are raising our full year 2023 expectations again this quarter.
Speaker 4: We now expect net revenue of 2.37 to 2.42 billion, which reflects high single digit revenue growth.
We now expect net revenue of $2 37 to $2 2 billion, which reflects high single digit revenue growth.
Due to higher revenues.
Speaker 4: We're raising our 2020, we adjusted EBITDA guidance to 540 to 550 million and adjusted the BS range between
We are raising our 2023, adjusted EBITDA guidance to $540 million to $550 million.
And adjusted EPS range.
Between 51.
Uhm.
Speaker 4: Let me now move on how strong financial performance is translating into the third pillar of value creation. That is higher cast generation.
Let me now move on how strong financial performance is translating into the third pillar of value creation.
That is higher cash generation.
Speaker 4: In 2023, in conjunction with higher profitability and our efforts to drive working capital improvements, our same third year today that rating cost low on an underlying basis has growing about 40 percent to 295 million compared to 213 million for the first nine months of 2022.
Into 2020 to 'twenty three in conjunction with higher profitability in our efforts to drive working capital improvements our September year to date operating cash flow on an underlying basis is growing about 40% to $295 million compared to $213 million for the <unk>.
First nine months of 2022.
Speaker 4: Going forward, we're focused on converting an increased amount of high EBITDA to operating cash flow as a function of tired getting further working capital improvements and thoughtful capital investments.
Going forward, we're focused on converting an increased amount of EBITDA to operating cash flow is a function of tire getting further working capital improvements and thoughtful capex investments.
In addition, as you may have noticed on form 8-K, we filed on October 17th we made important progress on our key legacy item.
Speaker 4: In addition, as you may have noticed on Form 8K, we filed on October 17th, we made important progress on the key legacy I-
Speaker 4: That is transitioning from an up sick corporate structure to a more traditional sick or structure. This transition was highly and technically nature, but has substantial cash flow benefits to our company as it enhances investor transparency and surf load by having only one class of common stock.
That is transitioning from an up C corporate structure to a more traditional CCAR structure with.
This transition was highly technical in nature, but has substantial cash flow benefits to our company as it enhances investor transparency and surf load by having only one class of common stock.
Speaker 4: This leads me to the fourth pillar of value creation and that will deliver it.
This leads me to the fourth pillar of value creation and that is deleveraging.
Speaker 4: With higher cost generation and many of the historical improvements, investments to expand our portfolio and infrastructure already made were in a very good position to further reduce that.
Higher cash generation in many of the historical improvements investments to expand our portfolio and infrastructure already made clear in the <unk>.
Very good position to further reduce debt.
Speaker 4: From 2019 to now, net leverage has come down from 7.4 to 4.6 times in the most recent court.
From 2019 to now net leverage has come down from seven four to four six times in the most recent quarter.
Speaker 4: We're focused on delivering consistent that reduction over the course of time, and we feel confident in our ability to achieve net debt to adjusted below 4 times in 2025.
We're focused on delivering consistent debt reduction over the course of time.
So confident in our ability to achieve net debt to adjusted EBITDA below four times in 2025.
I hope this overview of the key pillars of value creation for Mcl is helpful. Going forward, we're confident that the increased diversification of our business strong financial performance higher cash generation and further deleveraging will create substantial value.
Speaker 4: I hope it's over give the key pillars of value creation for MNL is helpful. Going forward, we're confident that the increased diversification of our business, strong financial performance, higher cost generation, and further leveraging will create substantial value. Let me now hand it back to Siraan.
I'll hand, it back to Sheila.
Thank you toss those in.
Speaker 3: In summary, Amnih has never been in a better position to drive substantial, sustainable, long-term growth. And we believe the best days are ahead for our company.
In summary, <unk> has never been better positioned to drive substantial sustainable long term growth and we believe the best days are ahead whatever company.
Speaker 5: Let's now open it up, Tony for Q&A.
Let's now open it up Tony for Q&A.
Thank you we'd like to ask a question you may do so my question Paul fully by one your telephone keypad.
Speaker 1: Thank you. If you'd like to ask a question, you may do so by pressing star followed by one on your telephone keypad. If you're paying for your question, please ensure your device is balanced with locally. And if you wish to evoke your question, please press star followed by two.
Thank you for your question. Thank you for your device.
And if he wishes.
Please christoff will look like.
Speaker 1: We will now take our first question and Balaji Prasad from Barclays. Balaji, your line is now open. Be full ahead. We will now take our first question and Balaji Prasad from Barclays.
We will now take our first question from <unk>.
Paul from box.
Your line is now open.
Well as you please in July.
Okay.
Operator, we can go to the next.
Speaker 2: Operator, we can go to the next participant and put a velocity backing cue. Thank you.
Participant input velocity back in queue. Thank you.
Speaker 1: Okay, no problem. We will now take on questions. Then David.
Okay. No problem, we will now take our next question.
David.
A couple for us.
Speaker 6: couple. So, first, I wanted to ask you about
Wanted to ask you about.
<unk> care.
Speaker 6: And it's role in the organization going for them. Is that a business that you think might be non-core?
And its role in the organization going forward I mean is that a business like that.
Frank.
Might be noncore overtime.
Speaker 6: over time. How do you think about it strategically?
How do you think about it strategically that's number one number two regarding our injectable.
Speaker 6: That's number one. Number two, regarding injectables and all the launches that you cite, are these mostly shortage products? Are there any mix of shortage products and complex products? I'm just trying to understand how to think about the product niche here in injectables and what the margin structure for injectables is going to look like. Over time, margin structure, these are the appropriate margin structure. Thanks.
All of the launches that you cite or at least mostly shortage products.
Or is it a mix of shortage products.
<unk> products I'm, just trying to understand.
Think about the product next year in Injectables and what the margin structure for Injectables is going to look like.
Over time the margin structure of these corporate margin structure.
Okay.
Okay.
Speaker 5: Hey David, how are you? Good morning. On Evkett, as you know, we are very few remaining US manufacturers, that is where most of the businesses driven through TA combined products.
Hey, David how are you good morning on <unk> as you know.
Very few remaining U S manufacturers that is where most of the business is driven through Ta combined products.
Speaker 5: So it is strategic business for us. It grows as you can see the number of products for VADOD. Plus we have niche Unicdoz as well.
It is strategic business for us.
And grows as you can see the number of products for <unk>.
Plus we have a niche unit dose as well.
Speaker 5: And as you know, we have a partner who is expert in this area as running the business.
And as you know we have a partner who is expert in this area is running the business.
Speaker 5: So I would be an exact definition of coal non-core, but it is very strategic at this point for us, but we're open to value adoptions in the future. It is a strong business, highly profitable, and we're very committed to it.
So I would I mean exact definition of core non core but it is very strategic at this point for us, but we are open to value adoptions.
In the future it is a strong business.
Really profitable and we're very committed to it.
The second part I'm going to pass it to two gentlemen, since we have everybody today.
Speaker 3: The second part, I'm going to pass it to two gentlemen, since we have everybody today in the conference room. We'll start with my brother and he'll pass it to her share. Hi, David, good morning.
The conference room, we're going to start with my brother annual pass it too sure Hi, David Good morning.
Speaker 3: On injectable, we have a very big portfolio and we invested for last two years on expanding our R&D capabilities and also infrastructure. So we have a very wide variety of for dosage from capabilities, PFAs, large bags, auto injectors.
<unk> injectable we have.
Already big portfolio and reinvested.
Last two years on expanding our R&D capability and also infrastructure. So we are already wide variety of dosage form capabilities PFS large bags in auto injectors LIBOR thermal peptides microspheres. These are complex categories and some are also volume. So we have now capabilities.
Speaker 3: like the normal peptides, microspheres. These are complex categories and some are also volume. So we have now capabilities to play value and volume game both in the injectable space going forward. Where our current capacity was around 2025 million, while the PF has combination of different products.
To play value and volume game, both in the injectable space going forward, we're at our current capacity.
Currently 25 million, while our PFS combination of different products.
Speaker 3: is gone up to about 70 million. So that's a big shift. So second question of shortage is, we have about 30 products that's pending approvals or already approved. And the shortage products goes in and out, but Emnell is very much passionate about dressing the shortage issue. And we, as soon as we have product, we try to help alleviate the shortages.
Had gone up to about $70 million. So thats a big ships. So second question on shortages, we have what 30 products bats, pending approvals or already approved and the shortage products growth keep in and out but and Neil.
Is ready much passionate about addressing the shortage issue and we as soon as we have a product we try to help alleviate the shortage is.
Speaker 3: And some of the launches your question was, it's a mix. Some of our first two market products.
Some of the launches your question was.
Mix somewhat faster market products.
Speaker 3: some of our complex products like MBA multidos. So it's a combination of both and that's what we'll see in coming years and we are confident to launch you know 20 new products also in injectable in 2024. So very strong pipeline which we expect to expand about 80 products by 2025. I'll shift anything to it. David, I just build one thing to frame your comment packages.
Somewhat complex products like NBA multi dose.
It's a combination of both and that's what we'll see in coming years, and we are confident to launch 20, new products also an injectable in 2024, so a very strong pipeline reaches that could expand to about 80 products by two.
2025 per share anything to add David I'll, just build one thing to frame your comment Craig bridges.
Speaker 3: I think shortages and complex products are not mutually exclusive. Often the biggest shortages are on complex products.
I think shortages and complex products are not mutually exclusive often the biggest shortages are on complex products as you see us launch our last six months at a pretty good proxy for the portfolio, which is premixed bags electric lights, which are a structurally short category, where there are structural issues in the market over the long term that we hope to address them.
Speaker 3: As you see, as launch, our last six months are pretty good proxy for the portfolio, which is premixed bags.
Speaker 3: electrolytes, which are a structurally short category where there are structured dishes in the market over the long term that we hope to address.
Speaker 3: And single product opportunities where we have structural strengths, like the cortical steroids method, prednis, learn others, but you should expect us to continue to proceed along a pathway like.
Good product opportunities, where we have structural strengths like the corticosteroid methylprednisolone than others, but you should expect us to continue to proceed along the path we like that.
Speaker 4: And David, on the first margin. Yeah. Yeah. Yeah. Okay. You're last point goes impact to the margin. So you're injectables in general and the areas we play.
And David on the.
Gross margin yes.
Yes.
Yes, that's okay.
The last point was impacted a margin so injectables in general in the area of Sweet play.
Speaker 4: are just going to be accretive to the overall gross margin of the company. So this is one of the reasons why as we think about the future, we feel confident about any enhancing and increasing our financial, not only top line profitability and just a little bit in cash growth.
Just they're going to be accretive to the overall gross margin of the company. So this is one of the reasons why as we think about the future.
We're confident about the enhancing and increasing our financial not only top line profitability and.
Adjusted EBITDA and cash growth.
Speaker 6: Okay, got it. That got to my last question. Thank you.
Okay got it that got to my last question. Thank you.
Thank you.
Thanks, David.
Okay.
Speaker 1: Thank you David. As I remind that, you can show you have a website sponsored. Both are asking your question to prevent any audience.
Thank you David as a reminder.
Web com.
Whilst asking a question anyway.
Okay.
Okay.
Speaker 1: We will now take on next question from Liz Salowski from Truist.
We will now take our next question from Matt.
Hello, Keith.
Hi.
Yes.
Good morning, Thank you for taking my questions.
Speaker 2: Good morning. Thank you for taking my questions. Just first on the right Terry front, the script growth has been good. How about the sales figure was a bit light. So just proud we've walked us through some of the the pricing dynamics in 3Q with any discounting in the GTN front.
First on the Rytary from the.
Script growth has been.
Good I'll call. It the sales CAGR was a bit light just perhaps walk us through some of the pricing dynamics into retail was there any discounting in the <unk> front.
Speaker 2: And then, secondarily on the IPX 203, can you provide a little bit more detail around the feedback from the FDA regarding your type A meeting and the study design that you expect for that? And then also, how are you thinking about commercial launch in the second half?
And then secondarily on the IPX tier three can you provide a little bit more details around the feedback from the FDA regarding your type a meeting.
And the study design that you expect for that and then also how are you thinking about the commercial launch in the second half.
Great. Thank you Les I'm going to have a chief commercial officer, Joe Randell answer the right question and then we'll move to my brother.
Speaker 7: Great. Thank you, Les. I'm going to have our Chief Commercial Officer Joe Renda answer the Rytary question, and then we'll move to my brother for IPX2 or three more details. Please. Yeah. So your question on Rytary, nothing has changed with our contracting strategy. We're still fortunate enough with Rytary to have the best coverage of any prescription product in the Parkinson's space. We have about 70 or so percent commercial coverage.
The next two or three more details. Please yes. So your question on Rytary.
Nothing has changed with our contracting strategy, we're still fortunate enough with rytary to have.
The best coverage of any prescription product in the Parkinsons space, we have about 70, or so percent commercial coverage and about 60 or so percent part D coverage.
Speaker 7: and about 60 or so percent of part D coverage. We actually, the growth we've seen has been, and they're a lot of part of the year. If you look at Q3 and Q4 as an example, our NBRX growth is in around 20 to 22 percent.
We actually the growth we've seen has been in the latter part of the year. If you look at Q3 and Q4 as an example.
Our <unk> growth is at around 20% to 22%, which is significantly higher than what we saw at the same time last year. So we are seeing both MD Rx growth with Rytary as well as Trs growth. So we've been really pleased with the with the pattern that we're seeing as we round out this year and overall this year.
Speaker 7: which is significantly higher than what we saw at the same time last year. So we are seeing both MBRX growth with Rytary as well as TRX growth.
Speaker 7: So we've been really pleased with the pattern that we're seeing as we round out this year. And overall this year, it looks like our growth will be higher than what we've seen in previous years with Rytary.
Looks like our growth will be higher than what we've seen in previous years with rytary.
Speaker 4: And unless just on your point about the quarterly gross to net, yeah, we had about 5-6 million dollars of over unfavorable kind of timing gross to net adjustment related to Medicare rebates, so that's why probably the quarterly net revenue growth is that a little less of the kind of volume growth. But you know, that's behind us and it was more of a one time event.
And last just on your point about the quarterly gross to net yes, we had about $5 $6 million.
Or an unfavorable kind of timing.
As to net adjustment related to Medicare rebates. So that's why probably quarterly net revenue growth.
Is that a little less of the kind of volume growth, but that's behind us and it was more of a one time one time event.
Speaker 3: I like this into on IPX 203. We had a very successful Taipei meeting to align our path forward with FDA. So question was mainly on the safety breach for carbidopa.
Alright.
Highlight this into on.
<unk> two or three.
We had a very successful type a meeting to align our path forward with FDA. So question was mainly on the safety bridge for card with Oba.
Speaker 3: And we have addressed that for the major as we had a one year of safety data on carbidopa.
We have addressed that for the major as we had one year of safety data on <unk> and FDA is aligned on our our data and what we have presented.
Speaker 3: and FDA is relying on our data and what we had presented. And it leads to only one remaining question because anytime Carbidopa has been a whole molecule, there's certain amount of Carbidopa we had to do a QT bridging study. So we are doing a small-truthing QT study in a 36-heldipation.
And it leads to only one remaining question because anytime guided me, though has been all molecule.
The amount of capital, but we had to acuity bridging study. So we are doing a small grouping Qt study and a 36 calibration, which we are starting very shortly in a weeks time and we.
Speaker 3: which we are starting very shortly in a week's time.
Speaker 3: And we plan to complete that study and file in first half of 2024 and launch product in second half of 2024.
To complete that study and file.
In first half of 'twenty 'twenty four.
And launched product in second half of 'twenty 'twenty four.
Speaker 3: We are ready to launch the product from the commercial and also from the manufacturing and the product is ready to go.
We're ready to launch the product from the commercial and also from the manufacturing and the product is ready to go.
Speaker 5: We are very excited on IPX203 and what value it brings to the patient. Yeah, it's a much broader value, less than Riteri. We're going after an entire 1 million patient population and 90,000 new patients come on every year, unfortunately.
Very excited on IP extra work again, what value it brings to the patient yes, it's a much broader value less than <unk>, we are going after and tier 1 million patient population and 90000, new patients come on every year. Unfortunately, so it's a large market and we wanted to change.
Speaker 5: So it's a large market and we want to change.
Speaker 5: the habits of prescription of prescribing IR to start with. Why not IPX203, it's much better formulation. It gives a good on time, longer good on time every day.
The habits of prescription prescribing IR to start with why not IPX, two or three it's much better formulation. It gives a good on time longer longer good on time every day.
Meaningful a huge impact on their daily lives, so and we have lots of obviously data to go with and we never marketed to the broader audience of broader broader patient population. So that is who we are ready for the marketing strategy. We have learned a lot from rytary.
Speaker 5: Obviously data to go with and and we never marketed to the broader audience of broader broader patient population. So that is.
Speaker 5: We are ready for the marketing strategy. We have learned a lot from rightary launch and obviously there is a lot of support for this product as the clinicians have seen the results of this product. It's extremely exciting launch coming up and not only in the United States we are at a final negotiation in Europe because Europe only has I.I.
Launch and obviously the.
There is a lot of support for this product as the clinicians have seen the results of this product so extremely exciting launch coming up in not only in the United States.
Final negotiation in Europe, because Europe only has and.
Speaker 5: And that'd be much needed for Parkinson's patient there. And globally, we're going to push it out to our mission to provide high-quality, life-changing medications to affordable access to global population.
And that would be much needed for Parkinson's patients that and globally.
We're going to push it out to.
Due to our mission to provide high quality life changing medications to affordable access to global population.
Exciting.
Speaker 8: And we're filing the response only. That's great. Thank you for all that.
And we're filing the response earlier.
Thank you for all that 'twenty one yes.
Speaker 2: Got it. Thank you for that color one for that color one.
Got it thank you for that color.
One.
Go ahead <unk> you have a follow up.
Speaker 1: Sorry, I muted his line. Let me open his line back up.
Alright, I need at his line.
I think from the linebacker.
Oh.
Speaker 1: Yes, there's a lot of feedback on the line.
Alright, Thanks, a lot.
That comes from the line.
Thanks.
Can you hear me now can you hear me, yes. We can go ahead, we can hear you now.
Speaker 2: Can you hear me now? Can you hear me now? Yes, we can hear you now.
Yes.
Okay.
Speaker 2: Okay, there seems to be a lot of feedback online. My follow-up question was regarding your recent refinancing agreement. So can you just perhaps walk us through some of the key aspects and changes in the covenants and things of that nature? Thank you.
Seems to be a lot of feedback on line.
My follow up question was regarding our recent finance refinancing.
Agreement. So can you just perhaps walk us through some of the key aspects and changes in our covenants.
Things of that nature. Thank you.
Okay.
Yes, Thanks Nate.
So we're pleased to report that after.
Speaker 4: So, you know, we're pleased to report that after, as you know, refinancing our term loan B, which was due May of 2025, was one of our key priorities of this year. And I think we're very pleased with the.
You know refinancing our term loan b.
Which was due may of 2025 was one of our key priorities. This year and I think we're very pleased with the with the outcome. So far so after just a lot of very positive support from our existing lenders and the number of new lenders, we successfully priced and not located.
Speaker 8: with the outcome so far. So after just a lot of very positive support from our existing lenders.
Speaker 8: and a number of new lenders were successfully priced and allocated.
Speaker 4: about $2.3 billion, which is about 90% of our term loan fee.
About $2 $3 billion, which is about 90% of our term loan b.
Speaker 4: And with that, the key thing was we extended the maturity by three years to May of 2028. So essentially, a couple hundred million dollars are due in May of 2025.
And with that the key thing was we extended the maturity by three years through May of 2028, so essentially.
A couple of hundred million dollars are due in may of 2025.
Speaker 4: and $2.3 billion have been pushed out to May 2028, essentially four and a half years from now, which gives us a substantial amount of additional runway for the company to continue the diversification path that we began a few years ago, increasing our cash generation that I spoke of and reducing both absolute debt and net debt to adjusted EBITDA.
And $2 $3 billion have been pushed out to May 2028, essentially four and a half years from now which gives us a substantial amount of additional runway for the company to continue the diversification that we began a few years ago.
Increasing our cash generation that I spoke of and reducing both absolute.
Debt and net debt to adjusted EBITDA.
Speaker 4: As we expected, the pricing was pretty much in line with our expectations. So you may have seen on Bloomberg, Nate, it was SOFR plus 550 basis point. That's a couple hundred, 200 basis points over the existing loan. So that was within our expectations.
As we expected the pricing was pretty much in line with our expectations. So you may have seen in blue on Bloomberg. It was software plus 550 basis points.
That's a couple hundred 200 basis points over the existing loans, so that was within our expectations.
So that leads to about $50 million of the increase in interest expense.
Speaker 4: So that leads to about $50 million of increase in interest expense.
Which.
Speaker 4: the unwinding of the APS-C I spoke about will more than offset that increase.
The unwinding of the FCA spoke about will more than offset that increase so from an overall.
Speaker 9: So from an overall cost perspective, that increase in interest expense, which we fully expect it will be more than offset by our changing corporate structure, which will save us about $60 million plus year over year.
Cost perspective that increase in interest expense, which we fully expect that it will be more than offset by our change in corporate structure, which will save us about $60 million plus.
Year year over year.
Speaker 9: You know, in terms of cabinets and so forth, you know, there is nothing kind of big material changes that I can I can fully recall.
In terms of covenants and so forth.
There is not being kind of big material.
Changes that I can I can fully.
Recall and then the final thing I would mention is closer.
Speaker 4: And the final thing I would mention is also, you know, we need to keep in mind.
We need to keep in mind.
Speaker 9: that our interest expense growth is limited partially because a billion three of our debt is fixed.
That our interest expense growth is limited partially because a building on three of our debt is fixed.
Speaker 4: So with a swap in place, we were able to amend that swap to kind of reduce our interest expense associated with this refinancing. So great outcome from our perspective. I wanna thank both our existing lenders.
We have a swap in place.
We were able to.
A man that swap.
To kind of reduce our interest expense associated with this refinancing so great outcome from our perspective.
Both our existing lenders.
Speaker 9: into our term loan for being supportive and, you know, working with us over the last few months, because as we know, the capital markets, you know, have been pretty choppy.
I mean.
Our term loan.
For being supportive in working with us over the last few months.
Because as we know the capital markets.
It can be pretty choppy.
Great. Thank you.
Okay.
Speaker 1: Thank you, Les. We will now take our next question from Nathan Rich.
Thank you we will now take our next question from Nathan Rich.
Paul.
Speaker 10: from Goldman Sachs. Your line is now open, please go ahead.
From Goldman Sachs. Your line is now open. Please go ahead.
Speaker 11: Hi, good morning. This is Sarah on Bernate. Thank you so much for taking our.
Hi, Good morning. This is Sarah on for Nate. Thank you so much for taking our questions.
Speaker 11: I first wanted to start on the new corporate structure and the cash flow implications. Can you just talk about the peak expected restructuring savings and also the timeline to realize these synergies?
First wanted to start on the new corporate structure and the cash flow implications can you just talk about the peak expected restructuring savings and also the timeline to realize these synergies.
Speaker 9: So, good morning, Sarah. So, as people know, in this room, it took us a couple of years to kind of fully get our arms around the, the legacy structure and really finding the best way that works for all our shareholders.
So good morning, Sarah.
So.
People know <unk>.
It took us a couple of years to kind of fully get our arms around the the legacy structure and really finding the best way that works for all our shareholders.
Speaker 9: So, number one is we expect to effectuate the change essentially tonight.
So number one is we expect to effectuate the change.
Essentially tonight so so.
Speaker 9: So as of tonight, we'll get that new corporate structure and the savings will become immediate, number one.
So as of Tonight, we will get that new corporate structure and the savings will become immediate number.
Speaker 9: Our expected savings per year is about $60 million of cash every year.
One.
Our expected savings per year is about $60 million.
Costs every year.
Speaker 9: like those historic levels of cash was exiting the company as cash from Financing that was in that specific cash flow line
Those historic levels of cost was exiting the company as cash from.
Financing that was in that specific cash flow line.
Speaker 9: So those those savings will be materialized and will be accretive to the company essentially immediately as those kind of tax distribution payments cease as of tonight.
So those those savings will be materialized and will be accretive to the company esque.
Essentially immediately as those.
Tax distribution payments seats as of Tonight great.
Speaker 4: a great outcome. Some companies, I don't know how much you know about that, some companies
Great outcome, some companies, but I don't know how much you know about that some companies.
Speaker 9: given one of those structures by paying hundreds of millions of dollars out. We did not. It cost us zero to unwind this structure. We feel great about the outcome.
Kevin one of those structures by paying hundreds of millions of dollars out we did not.
It cost us zero to unwind this structure.
Feel great about the outcome.
Speaker 11: That's really helpful. Thank you. And then I just wanted to dive into the strong ab care growth and the segment's operating margin improvement. So, can you talk about what drove the significant margin uplift in the quarter? And then also, I know GLP-1s have been a big area of focus, is this also contributing to the strength in this segment?
That's really helpful. Thank you and then I just wanted to dive into the strong growth.
The segment's operating margin improvement. So can you talk about what drove the significant margin uplift in the quarter and then also I know TL coupons have been a big area of focus is this also contributing to the strength in the segment.
Speaker 12: Let me take the show so.
Let me pick the so so.
Speaker 9: This after, as you know, you may know, we acquired 65% of our care in January 30th of 2020. And since then.
This is Oscar.
As you May know web acquired 65% of Bob occur in January 30 of 2020, and since then even in periods of Covid and et cetera that business has been proven incredibly resilient.
Speaker 9: Even in periods of COVID and et cetera, that business has been proven incredibly resilient.
Speaker 9: Point number one, point number two is part of our strategic rationale is
And growing.
Point number one point number two is part of our strategic rationale is was kind of how do we leverage <unk> pipeline of products.
Speaker 9: was kind of how do we leverage MDL's pipeline of products.
Speaker 9: to accelerate the historic growth of ad care. And that has played exactly as we thought. There's been a tremendous amount of product flow from ad care to, excuse me, from MDL to ad care that has created tremendous amount of value to the patients.
<unk>.
Accelerate.
The historic growth Obama care and that has played exactly as we thought.
There's been tremendous amount of product flow from <unk> to <unk>.
From excuse me from NPL to ask here that has created tremendous amount of value to the patients and the buyers and the ultimate customers about care.
Speaker 9: and the buyers, right, and the ultimate customers of our care.
Speaker 9: So that growth has been driven by a couple of different reasons. Number one is the overall demand in the marketplace as population ages right.
So that growth has been driven by a couple of different reasons number one is.
Overall demand in the marketplace as the population ages right.
Speaker 9: And we have a natural what I will call tailwind, number one.
And that we have and not too Robert what I will call tailwind number one.
Speaker 9: Number two, there is simply kind of coming out of COVID, there is simply more product availability, both from MNL as well as the third-party providers that Adcare works with. So, new product introductions can fuel that.
Number two there is simply kind of coming out of Covid. There is simply more product availability, both from <unk> as well as the third party providers.
<unk> works with so new product introductions fuels that number three we've talked about shortages in the market place associated not only with injectables, but in general complex products.
Speaker 9: Number three, we've talked about shortages in the marketplace associated not only with injectables, but in general complex products.
Speaker 9: So, I was able to kind of tactically take advantage of certain shortages in the marketplace this year and price accordingly. So that's what.
<unk> was able to tactically take advantage of certain.
Shortages in the marketplace this year and price accordingly, So that's why you see some of the increased gross margin.
Speaker 9: why you see some of the increased growth margin in our performance. This work ended up in actually here today, versus prior years.
In our performance this quarter and actually year to date versus prior years.
Speaker 4: So overall, those were the reasons why the growth of healthcare has been strong. And we continue to expect, you know, not sure that the business will continue to be growing 25, 30% upline every year, but definitely we're expect strong double digit growth for the next few years to follow. Does that help, sir? So Sarah, I just want to clarify that condition.
Overall.
Those were the reasons why the growth has been strong and we continue to expect.
Im not sure that the business will continue to be growing 25%, 30% top line every year, but definitely we're expecting strong double digit growth for.
For the next few years to follow as it helps there.
So Sarah I, just wanted to clarify that <unk> is a niche government distribution business for the year.
Speaker 5: government distribution business for VADOD.
Speaker 5: where you have to invest in a product development, product partnership way in advance.
Where do you have to invest in the product development product partnership way in advance. So it's a value added distribution not just simple distribution.
Speaker 5: So it's a value-added distribution, not just simple distribution. We do not distribute GLP-1s or anything. So the growth is from value-added generics products from Amnil, as well as other suppliers that F-Care is set to do government contracting for long-term national contracts, as well as FSS schedules. And their unit dose business with the hospitals is growing as well.
We do not.
Distribute DLP ones or anything so the growth is from value added genetics products from Neal as well as other suppliers that <unk>.
<unk> is set to do government contracting for long term national contracts as well as FSS schedules and.
The unit dose business with hospitals is growing as well.
That's really helpful. Thank you.
Yes.
Speaker 10: Thank you. We will now take our next question from Balaji Prasad from Barclays. Balaji, your line is now open, please go ahead.
Thank you we will now take our next question from <unk> Prasad from Barclays.
Your line is now open. Please go ahead.
Speaker 13: Thank you. Hi. Good morning, everyone. And apologies for missing the previous opportunity. So thanks again for that. A couple of questions from me.
Thank you hi, good morning, everyone.
Apologies for missing the payments opportunity.
Again for that.
Couple of questions from me Firstly, it's great to see the Delta of the company over the past couple of years, especially the last two quarters.
Speaker 13: Firstly, it's great to see the development of the company over the past couple of years, and especially the last two quarters, the transformation has been pretty solid.
The transformation has been pretty solid.
Speaker 13: As I look out over the next one or two years, I would love to understand the pushes and pulls that we can expect for the cash flow, for 24-24.
As I look out over the next one to two years now to understand the pushes on phones that we can expect for the cash flow for 'twenty four 'twenty five.
Speaker 13: see how we can think about the cash road trends for the next two you definitely flipped around the traditional generic model in looking at going after the markets in India and China I'd love to get your sense get a sense of how Large these markets can be considering that both of these markets Are at different than respect from India seems to be on a very strong growth platform whereas China seems to have told and how would your approach these markets differently thank you
See how we can think about the cash flow trends for the next year.
Two.
Definitely flipped around the traditional generic model and looking on going after the market.
Beyond China.
I'd love to get your sense.
Get a sense of how large these markets can be considering that both of these markets.
Our friends in the spectrum and that seems to be on a very strong growth platform that is China seems to have stalled and how would you approach. These markets differently. Thank you.
Okay.
Speaker 9: Able as a good morning, I'll take the 1st 1. so as we think the next next few years, you know, we continue to drive incremental revenue, incremental EBITDA and incremental costs.
<unk> good morning.
I'll take the first one so we think the next next few years, we continue to drive incremental revenue incremental EBITDA and incremental costs.
Speaker 9: No, no, no question about it. And the incremental costs. So, if you look at our costs to EBITDA this year, it was over 50%, much more favorable than prior years, because we intentionally focused on certain working capital improvements.
No question about it.
And the incremental cash.
So if you look at.
Our costs to EBIT. This year it was over 50% much more favorable than prior years, because we intentionally focused on certain working capital improvements.
Speaker 9: Our expectation is that we'll continue to grow. So Zibbida grows, operating costs will continue to grow. That's point number one.
Our expectation is that we'll continue to grow so as EBITDA grows operating cash will continue to grow that's point number one.
Speaker 9: Point number two, in terms of, you know, you also know that copics were pretty much at scale.
And number two in terms of you also know that Capex, we're pretty much at scale. So we typically spend between $50 million to $60 million, maybe it goes a little higher maybe goes a little lower but because we are at scale, we don't expect capex to substantially change okay.
Speaker 9: So, we typically spend between 50, 60 million dollars, you know, maybe it goes a little higher, maybe it goes a little lower, but because we are at scale, we don't expect CAPEX to substantially change. Okay. We talked about an increase of interest expense, so maybe that goes up, call it 50 million dollars year over year. Okay.
We talked about an increase of interest expense. So maybe that goes up call it $50 million year over year Okay.
Speaker 9: but also we will save year over year over $60 million of cash distributions related to the APC and unwound. So, the net of the two is a positive, call it $10 to $15 million.
Also we will save year over year over $60 million of cash distributions related to the FCA unwound. So the net of the two is it positive call. It 10 to 15 million $10 million to $15 million.
Speaker 9: So, and the other thing is, in terms of settling, one of the other things, you know, about us is, is who've been very focused on kind of cleaning up legacy issues. Okay. So, back in twenty nineteen.
So and the other thing is in terms of settling one of the other things you know about does his who've been.
Very focused on kind of cleaning up legacy issues. Okay. So back in 2019, we will.
Speaker 9: Not only us, but the whole industry was facing substantial amount of liabilities and not a lot of clarity around it. Okay. So, as you know, a couple of years ago, we settled the OPANA ER. So, last year, we had a hundred and thirty some million dollar payment related to that.
Not only us, but the whole industry was facing substantial amount of liabilities and not a lot of clarity around okay.
So as you would know a couple of years ago, we settled the Opana ER. So last year, we had $137 million payment related to that.
Speaker 9: This year, we had an $86 million payment, and there is only one payment of $50 million remaining in January of 2024. So 2024 versus 2023, right, it's $30 million less of a headwind.
This year, we had an $86 million payment and there is only one payment of $50 million remaining in January of 2024. So.
2024 versus 2023, right, it's $30 million less of a headwind.
Speaker 9: regarding the OPANA ER, right? So that's going to be a positive. And then after that, right, OPANA is behind.
Regarding the Opana ER right, so that's going to be.
Positive and then after that right partner is behind us.
Speaker 9: There are certain other liabilities, you know, we talked about opioids, you know, our team is working really hard. We've put a placeholder.
Sit down the liabilities we talked about.
Opioids are division working really hard we've put in place hold theyre pretty well educated estimate of about $22 million and our balance sheet for that potential liability there may be a little bit more maybe a little less and that as you know usually those liabilities settled over.
Speaker 9: pretty well-educated estimate of about $22 million in our balance sheet for that potential liability. It may be a little bit more, it may be a little less.
Speaker 9: And as you know, usually those liabilities get settled over a long period of time, multiple years.
Long period of time over multiple years. So we don't we don't believe thats going to be given material impact at any given year.
Speaker 9: So we don't we don't believe that's going to be given material impact at any given.
Speaker 9: So, so overall, I think when you look at all of those pieces, I think there is more cost that stays in the company over the next few years and growing than in prior year.
So overall I think when you look at all of those pieces I think there is more cost that stays in the company over the next few years and growing.
Prior years.
Speaker 5: Thank you, Dr. Sousa. And international biology, we are.
Thank you, Doug so as an international apology.
Sure.
Two strategies, we have one is using our Muse owned portfolio, which is very huge.
<unk>.
The retail side as well as in the future could be biosimilars.
We are partnering in Europe.
Brian 100 years old Finland company as our partner so we're working through their sales channel to sell the product and new products.
Speaker 5: Middle East, we just signed up multiple partnerships. So we'll be selling Amneel's product in Middle East. And USFT approved sites, approved products, obviously has more premium than the other products.
Middle East, we just signed up multiple partnership so it will be selling this product in middle East.
And U S. FDA approved sites approved products, obviously has.
More premium than the other products.
Speaker 5: We have finalized our term sheets on Southeast Asia as well, and going now to South America, Canada. So, we'll cover pretty much the entire world, some parts of Africa as well.
We have finalized or term sheets on southeast Asia, as well and going now to South America, Canada. So we will cover pretty much the entire world some parts of Africa as well.
And basically it would be an incremental revenue of amnion products, which are sold in the United States. So that's the first set of strategy, which we expect to go to $500 million plus 15, it will keep growing because we are more and more products that we're launching and again complex products and international.
Speaker 5: Basically, it'd be an incremental revenue of Amnil's product which has sold in the United States.
Speaker 5: So, that's the first strategy, which we expect to go to 50, 100 million, plus it can, it will keep growing because we have more and more products that we are launching. And again, complex products and international markets are very good. We're not taking every product out there. It has to obviously make certain margins for us. And the second strategy is India strategy. That is a standalone strategy.
Markets are really good we are not taking every product out there.
Has to obviously make.
Are the margins for us.
The second strategy is India strategy that is a standalone strategy that we are we have direct marketing.
Speaker 5: That we are, we have direct marketing. We have spent quite a bit time understanding the market.
We have spent quite a bit of time understanding the market and we have launched our sales forces in hospital several products and growing diagnostic in hospitals and now we're just expanded ophthalmology.
Eyecare products portfolio in India, and we will be entering.
Oncology and CNS as well, so pretty broad strategy, because we believe India, it's growing at a 14, 15% every year.
Pharma market and it has even more room to grow so we wanted to be part of that growth journey and we have the science.
We have the company's reputation and site up in India.
So we believe India can become substantial market, it's very small today like $10 million will keep growing.
But it has.
It can go pretty long way in India. So thats the international strategy, we have just their ability to add one thing in India. We are looking at beyond our current portfolio, especially in a relatively than some other areas.
Speaker 3: So that's the international strategy we have. Just Balaji, to add one thing in India, we are looking at beyond our current portfolio.
Speaker 3: especially in a rare disease and some other areas in India because there is a huge unmet needs on many, many products. So we are looking at certain branded aspect of product development and launching India specifics. And that looks pretty exciting that space because there is a lot more awareness, affordability.
<unk> in India, because there is a huge unmet needs on many many products. So we are looking at certain aspect of it.
Product development, launching and get specifics that looks pretty.
Exciting that space because there is a lot more awareness affordability.
Speaker 14: and people are talking about health and prevention than the previous time. So entire India market is shaping up very differently than what we have seen before. So we want to be there and we want to be evaluated something that is unique and new. Thank you all. Thank you all.
And people are you.
Or are.
We are talking about health and prevention than the previous times or in the India market is shaping up very differently than what we haven't seen before so we are if you wanted to be there and we want to be a value added something that is unique and new.
<unk>.
Thank you all.
Yes.
Okay.
Thank you Jay.
Speaker 10: We have no further questions registered today so with that I will hand over to Chirag Patel for final remarks.
My further questions registered today, so with that I will hand, David.
For final remarks.
Speaker 5: Well, thank you very much, everybody, and have a nice day.
Well, thank you very much everybody and have a nice day.
Speaker 1: This concludes today's call. Thank you all for your participation.
This concludes today's call. Thank you for your participation.
Sure.
Okay.
You may now disconnect your lines.
[music].
Speaker 15: You